Breast Cancer Task Force Must Take More Active Role In RFP Development, New Chairman Insists
In Brief: FDA To Review Preclinical Testing, Phase I Protocols At Open Advisory Group Meeting
FDA Pettiness Holds Up Trials with Promising Anticancer Drugs
FDA Proposes Guidelines For Testing New Anticancer Drugs
Breast Cancer Progress Report Summaries
Shubick Committee Support New System for NCU Review, Action On Chemicals
Trending Stories
- Franco Muggia, former head of CTEP and NYU cancer center, dies at 85
- House committee’s FY26 spending bill increases NCI funding by $48M, NIH by $99M
House joins Senate in rejecting Trump’s proposed 40% NIH cuts - Bhattacharya fields NCAB’s questions about funding, political involvement in grant review, DEI, animal testing
- Lowy: Forward-funding policy forced NCI to drastically reduce RPG awards funded for FY25, 10% of NCI staff has been lost
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - Robert A. Winn on his new vision to train cancer center leaders: “I had a big bold idea and an ‘Aha!’ moment.”